U.S. FDA’s Response To Heparin Scare Made With “Alacrity And Sound Judgment” – von Eschenbach
This article was originally published in PharmAsia News
Executive Summary
In a Feb. 15 e-mail to agency personnel, U.S. FDA Commissioner Andrew von Eschenbach said the U.S. FDA has responded to the recent import safety scare related to Baxter Healthcare's injectable heparin "with its customary alacrity and sound judgment.
You may also be interested in...
U.S. FDA Move “Beyond Our Borders” Begins With China
Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.
U.S. FDA Move “Beyond Our Borders” Begins With China
Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.
China State FDA Issues Warning In Wake Of Heparin Safety Concerns
SHANGHAI - In the wake of a U.S. safety scare related to Baxter Healthcare's heparin, China's State FDA has warned foreign pharmaceutical companies to conduct business with only licensed Chinese companies